Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychloro..
Iota-carragee..
Ivermectin
Melatonin
Molnupiravir
Nigella Sativa
Nitazoxanide
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
All studies
Exclusions
Mortality
ICU
Hospitalization
Serious outcomes
Cases
Viral clearance
RCTs
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Probiotics  COVID-19 treatment studies for Probiotics  C19 studies: Probiotics  Probiotics   Select treatmentSelect treatmentTreatmentsTreatments
Aspirin Molnupiravir
Bamlanivimab Nigella Sativa
Bromhexine Nitazoxanide
Budesonide Povidone-Iod..
Casirivimab/i.. Probiotics
Colchicine Proxalutamide
Conv. Plasma Quercetin
Curcumin Remdesivir
Favipiravir Sotrovimab
Fluvoxamine Vitamin A
Hydroxychloro.. Vitamin C
Iota-carragee.. Vitamin D
Ivermectin Zinc
Melatonin

Other Adoption
Outcomes in COVID-19 probiotics studies
Outcomes in probiotics studies. The immune effects of probiotics are strain-specific and studies use different strains.
00.250.50.7511.251.51.752+Gutiérre.. (DB RCT)35%0.65 [0.53-0.80]no recov.69/147105/146Improvement, RR [CI]TreatmentControlVeterini29%0.71 [0.41-1.22]viral time15 (n)15 (n)Tau​2 = 0.00; I​2 = 0.0%Early treatment34%0.66 [0.55-0.80]69/162105/16134% improvementd'Ettorre87%0.13 [0.01-2.33]death0/284/42Improvement, RR [CI]TreatmentControlCeccarelli64%0.36 [0.18-0.68]death10/8834/112Li-12%1.12 [0.74-1.69]no disch.30/12341/188Zhang14%0.86 [0.77-0.96]hosp. time150 (n)150 (n)Tau​2 = 0.12; I​2 = 70.7%Late treatment27%0.73 [0.47-1.15]40/38979/49227% improvementLouca8%0.92 [0.85-0.99]casesImprovement, RR [CI]TreatmentControlAhanchian (DB RCT)73%0.27 [0.03-2.25]symp. case1/294/31Tau​2 = 0.17; I​2 = 21.8%PrEP20%0.80 [0.38-1.70]1/294/3120% improvementAll studies21%0.79 [0.67-0.93]110/580188/68421% improvement8 probiotics COVID-19 studiesc19probiotics.com Sep 24, 2021Tau​2 = 0.02; I​2 = 67.5%; Z = 2.79Effect extraction pre-specifiedFavors probioticsFavors control 00.250.50.7511.251.51.752+Gutiérre.. (DB RCT)35%0.65 [0.53-0.80]no recov.69/147105/146Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment35%0.65 [0.53-0.80]69/147105/14635% improvementd'Ettorre87%0.13 [0.01-2.33]death0/284/42Improvement, RR [CI]TreatmentControlCeccarelli64%0.36 [0.18-0.68]death10/8834/112Li-12%1.12 [0.74-1.69]no disch.30/12341/188Zhang14%0.86 [0.77-0.96]hosp. time150 (n)150 (n)Tau​2 = 0.12; I​2 = 70.7%Late treatment27%0.73 [0.47-1.15]40/38979/49227% improvementLouca8%0.92 [0.85-0.99]casesImprovement, RR [CI]TreatmentControlAhanchian (DB RCT)73%0.27 [0.03-2.25]symp. case1/294/31Tau​2 = 0.17; I​2 = 21.8%PrEP20%0.80 [0.38-1.70]1/294/3120% improvementAll studies21%0.79 [0.67-0.95]110/565188/66921% improvement7 probiotics COVID-19 studies after exclusionsc19probiotics.com Sep 24, 2021Tau​2 = 0.03; I​2 = 71.4%; Z = 2.57Effect extraction pre-specifiedFavors probioticsFavors control 00.250.50.7511.251.51.752+d'Ettorre87%0.13 [0.01-2.33]0/284/42Improvement, RR [CI]TreatmentControlCeccarelli64%0.36 [0.18-0.68]10/8834/112Tau​2 = 0.00; I​2 = 0.0%Late treatment66%0.34 [0.18-0.64]10/11638/15466% improvementAll studies66%0.34 [0.18-0.64]10/11638/15466% improvement2 probiotics COVID-19 mortality resultsc19probiotics.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.33Favors probioticsFavors control 00.250.50.7511.251.51.752+Ceccarelli15%0.85 [0.48-1.50]16/8824/112Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment15%0.85 [0.48-1.50]16/8824/11215% improvementAll studies15%0.85 [0.48-1.50]16/8824/11215% improvement1 probiotics COVID-19 ICU resultc19probiotics.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 0.57Favors probioticsFavors control 00.250.50.7511.251.51.752+Zhang14%0.86 [0.77-0.96]hosp. time150 (n)150 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment14%0.86 [0.77-0.96]0/1500/15014% improvementAll studies14%0.86 [0.77-0.96]0/1500/15014% improvement1 probiotics COVID-19 hospitalization resultc19probiotics.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 2.61Favors probioticsFavors control 00.250.50.7511.251.51.752+d'Ettorre87%0.13 [0.01-2.33]death0/284/42Improvement, RR [CI]TreatmentControlCeccarelli64%0.36 [0.18-0.68]death10/8834/112Tau​2 = 0.00; I​2 = 0.0%Late treatment66%0.34 [0.18-0.64]10/11638/15466% improvementAll studies66%0.34 [0.18-0.64]10/11638/15466% improvement2 probiotics COVID-19 serious outcomesc19probiotics.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 3.33Effect extraction pre-specifiedFavors probioticsFavors control 00.250.50.7511.251.51.752+Louca8%0.92 [0.85-0.99]Improvement, RR [CI]TreatmentControlAhanchian (DB RCT)85%0.15 [0.01-2.73]0/293/31Tau​2 = 0.56; I​2 = 33.6%PrEP33%0.67 [0.18-2.57]0/293/3133% improvementAll studies33%0.67 [0.18-2.57]0/293/3133% improvement2 probiotics COVID-19 case resultsc19probiotics.com Sep 24, 2021Tau​2 = 0.56; I​2 = 33.6%; Z = 0.58Favors probioticsFavors control 00.250.50.7511.251.51.752+Veterini29%0.71 [0.41-1.22]viral time15 (n)15 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment29%0.71 [0.41-1.22]0/150/1529% improvementLi-35%1.35 [1.13-1.62]viral time123 (n)188 (n)Improvement, RR [CI]TreatmentControlZhang17%0.83 [0.75-0.93]viral time150 (n)150 (n)Tau​2 = 0.11; I​2 = 95.1%Late treatment-6%1.06 [0.66-1.70]0/2730/338-6% improvementAll studies4%0.96 [0.65-1.43]0/2880/3534% improvement3 probiotics COVID-19 viral clearance resultsc19probiotics.com Sep 24, 2021Tau​2 = 0.10; I​2 = 90.7%; Z = 0.18Favors probioticsFavors control 00.250.50.7511.251.51.752+Gutiérre.. (DB RCT)35%0.65 [0.53-0.80]no recov.69/147105/146Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment35%0.65 [0.53-0.80]69/147105/14635% improvementAhanchian (DB RCT)73%0.27 [0.03-2.25]symp. case1/294/31Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%PrEP73%0.27 [0.03-2.25]1/294/3173% improvementAll studies35%0.65 [0.53-0.79]70/176109/17735% improvement2 probiotics COVID-19 Randomized Controlled Trialsc19probiotics.com Sep 24, 2021Tau​2 = 0.00; I​2 = 0.0%; Z = 4.29Effect extraction pre-specifiedFavors probioticsFavors control 00.250.50.7511.251.51.752+Veterini29%0.71 [0.41-1.22]viral time15 (n)15 (n)Improvement, RR [CI]TreatmentControlTau​2 = 0.00; I​2 = 0.0%Early treatment29%0.71 [0.41-1.22]0/150/1529% improvementd'Ettorre87%0.13 [0.01-2.33]death0/284/42Improvement, RR [CI]TreatmentControlCeccarelli64%0.36 [0.18-0.68]death10/8834/112Li-12%1.12 [0.74-1.69]no disch.30/12341/188Zhang14%0.86 [0.77-0.96]hosp. time150 (n)150 (n)Tau​2 = 0.12; I​2 = 70.7%Late treatment27%0.73 [0.47-1.15]40/38979/49227% improvementLouca8%0.92 [0.85-0.99]casesImprovement, RR [CI]TreatmentControlAhanchian (DB RCT)73%0.27 [0.03-2.25]symp. case1/294/31Tau​2 = 0.17; I​2 = 21.8%PrEP20%0.80 [0.38-1.70]1/294/3120% improvementAll studies15%0.85 [0.72-0.99]41/43383/53815% improvement7 probiotics COVID-19 peer reviewed trialsc19probiotics.com Sep 24, 2021Tau​2 = 0.01; I​2 = 54.2%; Z = 2.07Effect extraction pre-specifiedFavors probioticsFavors control 00.250.50.7511.251.51.752+Gutiérre.. (DB RCT)35%0.65 [0.53-0.80]no recov.69/147105/146Improvement, RR [CI]TreatmentControlVeterini29%0.71 [0.41-1.22]viral time15 (n)15 (n)d'Ettorre87%0.13 [0.01-2.33]death0/284/42d'Ettorre77%0.23 [0.01-4.63]ventilation0/282/42d'Ettorre88%0.12 [0.02-0.61]progression28 (n)42 (n)Ceccarelli64%0.36 [0.18-0.68]death10/8834/112Ceccarelli15%0.85 [0.48-1.50]ICU16/8824/112Li-12%1.12 [0.74-1.69]no disch.30/12341/188Li-60%1.60 [1.21-2.11]no disch.123 (n)188 (n)Li-35%1.35 [1.13-1.62]viral time123 (n)188 (n)Zhang14%0.86 [0.77-0.96]hosp. time150 (n)150 (n)Zhang14%0.86 [0.75-0.98]recov. time150 (n)150 (n)Zhang17%0.83 [0.75-0.93]viral time150 (n)150 (n)Louca8%0.92 [0.85-0.99]casesAhanchian (DB RCT)73%0.27 [0.03-2.25]symp. case1/294/31Ahanchian (DB RCT)85%0.15 [0.01-2.73]cases0/293/31probiotics COVID-19 outcomesc19probiotics.com Sep 24, 2021Favors probioticsFavors control
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit